The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)

Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Cze...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of hematology 2020-07, Vol.99 (7), p.1583-1594
Hauptverfasser:	Janikova, Andrea, Michalka, Jozef, Bortlicek, Zbynek, Chloupkova, Renata, Campr, Vit, Kopalova, Natasa, Klener, Pavel, Benesova, Katerina, Hamouzova, Jitka, Belada, David, Prochazka, Vit, Pytlik, Robert, Pirnos, Jan, Duras, Juraj, Mocikova, Heidi, Trneny, Marek
Format:	Artikel
Sprache:	eng
Schlagworte:	Hematology Lymphoma Medical prognosis Medicine Medicine & Public Health Oncology Original Article
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!